Earnings summaries and quarterly performance for Carisma Therapeutics.
Executive leadership at Carisma Therapeutics.
Board of directors at Carisma Therapeutics.
Research analysts covering Carisma Therapeutics.
Recent press releases and 8-K filings for CARM.
Carisma Therapeutics announces voluntary Nasdaq delisting and SEC deregistration
CARM
Delisting/Listing Issues
- Carisma Therapeutics Inc. (CARM) announced its Board of Directors approved the voluntary delisting of its common stock from Nasdaq and the subsequent deregistration of its common stock with the SEC.
- The company's common stock was suspended from trading on Nasdaq effective October 13, 2025, due to noncompliance with Nasdaq Listing Rules, and commenced trading on the OTCID market tier on the same day.
- Carisma anticipates filing a Form 25 with the SEC on or about December 15, 2025, with the formal delisting from Nasdaq expected to become effective on or about December 25, 2025.
- The decision to accelerate delisting and deregistration was made after considering a delist determination letter from Nasdaq and the company's ongoing pursuit of an orderly wind down of its operations.
Dec 5, 2025, 4:16 PM
Carisma Therapeutics Inc. Terminates Merger Agreement and Amends Moderna Collaboration
CARM
M&A
Delisting/Listing Issues
- Carisma Therapeutics Inc. terminated its merger agreement with OrthoCellix on September 16, 2025, due to OrthoCellix's failure to secure $25.0 million in concurrent financing.
- Following the termination, OrthoCellix is obligated to pay Carisma a $750,000 termination fee and $500,000 expense reimbursement by September 18, 2025, though payment is not yet confirmed.
- The company also amended its collaboration agreement with Moderna, receiving a one-time cash payment of $4.0 million in exchange for fully paid-up, perpetual, irrevocable, and royalty-free licenses for Moderna, eliminating future financial obligations from Moderna.
- Carisma now plans to pursue asset monetization and alternative strategic transactions, but faces a significant risk of delisting from Nasdaq by October 7, 2025, and anticipates limited or no cash distribution to stockholders if operations are wound down.
Sep 18, 2025, 1:15 PM
Carisma Therapeutics Inc. Provides Updates on Merger, Financing, and Nasdaq Listing
CARM
M&A
Executive Compensation
Delisting/Listing Issues
- Carisma Therapeutics Inc. is undergoing a Merger with OrthoCellix, Inc., a wholly-owned subsidiary of Ocugen, Inc., initially agreed upon on June 22, 2025. Upon closing, Carisma Therapeutics Inc. will change its name to OrthoCellix, Inc.
- As part of an anticipated Concurrent Investment, Carisma Therapeutics Inc. entered into a subscription agreement with Ocugen, Inc. on August 29, 2025, for Ocugen to purchase $5.0 million in common stock. The total anticipated Concurrent Investment is at least $25.0 million.
- Steven Kelly, President and CEO, entered into an Amended and Restated Employment Agreement and a Retention and Transaction Bonus Agreement on August 29, 2025, contingent on the Merger closing. He will continue as President and CEO and receive an option for 4.0% of the fully diluted capitalization post-Merger, along with potential retention and transaction bonuses.
- Carisma Therapeutics Inc. must complete the Merger and meet Nasdaq Capital Market listing requirements, including a $4.00+ bid price before the Merger closing, by October 7, 2025. The deadline for the $1.00+ bid price rule was extended to October 21, 2025.
Aug 29, 2025, 8:21 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more